RankingsPricing
  1. US-listed companies
  2. IONIS PHARMACEUTICALS INC
  3. Raw

IONIS PHARMACEUTICALS INCIONS

Market cap
$12.3B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2010		Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Cash and cash equivalents706512416014312985130279683398869276399242
Short-term investments------------1,7101,9322,056
Contracts receivable--------13637662269892
Inventories--------9182225222813
Other current assets759816151572102140140143168184218
Total current assets4833604237368378377981,1682,2082,7212,1312,3452,2032,6422,620
Property, plant and equipment, net36979186899093122132154181178747194
Right-of-use assets------------182172162
Deposits and other assets-------101328506075105127
Total assets5504855468479569569121,3222,6683,2332,3902,6122,5342,9903,004
Accounts payable7810111828212529161712182643
Accrued compensation798121216242529376639496870
Accrued liabilities121915223028366748679089140148108
Income taxes payable---------3310620
0.125 percent convertible senior notes, net----------293--44-
Current portion of deferred contract revenue--------160118108989115179
Other current liabilities------------899
Total current liabilities106767498115149134225280273583241312448309
Long-term deferred contract revenue--------567490424352288241157
1.75 percent convertible senior notes due June 2028.-------------562565
0 percent convertible senior notes due April 2026.-----------619622625629
Convertible senior notes, net--144150---533568------
Amount, after accumulated amortization, of the unamortized liability related to the sale of future royalties, pursuant to a royalty purchase agreement, that the Company is entitled to receive under collaboration agreements with Biogen and Novartis. The balance will be amortized over the estimated life of the arrangement using the effective interest rate method.-------------514542
Long-term lease liabilities------------179171162
Long-term obligations-------606060606094252
Total liabilities3063133634696987558139031,4811,5491,5461,8401,9612,6032,415
Common stock, $0.001 par value; 300,000,000 shares authorized, 157,908,815 and 144,340,526 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively000000000000000
Additional paid-in capital1,0001,0141,0771,3251,2251,3091,3111,5502,0472,2042,1141,9642,0602,2152,869
Accumulated other comprehensive loss1-1122140-14-30-32-32-25-21-33-57-33-31
Accumulated deficit-757-841-907-968-1,007-1,095-1,181-1,187-967-708-1,249-1,160-1,430-1,796-2,250
Total stockholders' equity2451711833782582011004191,1871,685843772573387588
Total liabilities and stockholders' equity5504855468479569569121,3222,6683,2332,3902,6122,5342,9903,004